Literature DB >> 15289403

Treatment of locally advanced breast cancer.

Deepu Mirchandani, Kamal Haider, Haji Chalchal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15289403      PMCID： PMC490055          DOI： 10.1503/cmaj.1040624

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  5 in total

1.  Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.

Authors:  M J Piccart; A Di Leo; M Beauduin; A Vindevoghel; J Michel; C Focan; A Tagnon; F Ries; P Gobert; C Finet; M T Closon-Dejardin; J P Dufrane; J Kerger; F Liebens; S Beauvois; S Bartholomeus; S Dolci; J P Lobelle; M Paesmans; J M Nogaret
Journal:  J Clin Oncol       Date:  2001-06-15       Impact factor: 44.544

2.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.

Authors:  Marc L Citron; Donald A Berry; Constance Cirrincione; Clifford Hudis; Eric P Winer; William J Gradishar; Nancy E Davidson; Silvana Martino; Robert Livingston; James N Ingle; Edith A Perez; John Carpenter; David Hurd; James F Holland; Barbara L Smith; Carolyn I Sartor; Eleanor H Leung; Jeffrey Abrams; Richard L Schilsky; Hyman B Muss; Larry Norton
Journal:  J Clin Oncol       Date:  2003-02-13       Impact factor: 44.544

3.  Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.

Authors:  M N Levine; V H Bramwell; K I Pritchard; B D Norris; L E Shepherd; H Abu-Zahra; B Findlay; D Warr; D Bowman; J Myles; A Arnold; T Vandenberg; R MacKenzie; J Robert; J Ottaway; M Burnell; C K Williams; D Tu
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

4.  Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Authors:  I Craig Henderson; Donald A Berry; George D Demetri; Constance T Cirrincione; Lori J Goldstein; Silvana Martino; James N Ingle; M Robert Cooper; Daniel F Hayes; Katherine H Tkaczuk; Gini Fleming; James F Holland; David B Duggan; John T Carpenter; Emil Frei; Richard L Schilsky; William C Wood; Hyman B Muss; Larry Norton
Journal:  J Clin Oncol       Date:  2003-03-15       Impact factor: 44.544

Review 5.  Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer.

Authors:  Tamara Shenkier; Lorna Weir; Mark Levine; Ivo Olivotto; Timothy Whelan; Leonard Reyno
Journal:  CMAJ       Date:  2004-03-16       Impact factor: 8.262
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.